The Wrap-Up: PropThink’s Top Picks this Week
Long Ideas - ResMed (RMD) is suing a new and low-cost competitor in the Continues Positive Airway Pressure market. The target, 3B Medical, isn’t taking the litigation lying … Continue Reading
Read nowSearch Results for kerx
Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
Long Ideas - Keryx Biopharmaceuticals (KERX) presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology (WVN) meeting during a … Continue Reading
Read nowKeryx: Attractive In Front Of Catalyst-Rich Second Half
Long Ideas - Shares of Keryx Biopharmaceuticals (KERX) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to … Continue Reading
Read now
Keryx, Zerenex, and IP Protection: A PropThink Conference Call
Interviews - On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former … Continue Reading
Read nowPropThink’s Week in the Life Sciences
Most Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read nowHere Are the Reasons to Own Keryx, and Why Key Catalysts are De-Risked
Long Ideas - Following PropThink’s conference call with Dr. Scott Chambers on Thursday, we’re quite comfortable with the short-term and long-term patent protection on Zerenex, Keryx’s (KERX) novel … Continue Reading
Read nowWhat You Need to Know About Keryx and Zerenex’s IP – A PropThink Expert Call
Long Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read now